Head-to-head · Cost-Efficiency Index
Layla vs Hers
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Layla
Cost-first shoppers who want brand-name GLP-1 access from shoppers who don't need a compounded/lower-cost option.
Visit LaylaHers
Cost-first shoppers who want brand-name FDA-approved GLP-1 access with a mainstream telehealth name.
Visit HersThe verdict
Layla takes it, leading the Cost-Efficiency Index 59 to 58. Layla is a US telehealth weight-loss brand that now sells only FDA-approved branded GLP-1s Ozempic, Wegovy, Zepbound and Mounjaro starting around $1,399/mo, all-inclusive of health check-ins, telehealth visits and unlimited doctor messaging. Hers still earns a C — Cost-first shoppers who want brand-name FDA-approved GLP-1 access with a mainstream telehealth name.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Layla.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Layla | Hers |
|---|---|---|
| Cost-Efficiency Index | 59/100 | 58/100 |
| Semaglutide / mo | $1,399/mo (brand Ozempic, promotional rate) | $348/mo (brand Wegovy, plus a separate fee) |
| Tirzepatide / mo | $1,399/mo (brand Mounjaro, promotional rate) | $448/mo (brand Zepbound, plus a separate fee) |
| Semaglutide / yr (modeled) | $16,788 | $4,176 |
| Tirzepatide / yr (modeled) | $16,788 | $5,376 |
| Coverage | Coverage not published | All 50 states |
| Oral / sublingual | Yes | No |
| Brand-name access | Yes | Yes |
| Rank here | #274 | #279 |
Layla
59/100Where the value is
- All-inclusive pricing bundles health check-ins, telehealth visits, prescription and unlimited doctor messaging into one price
- Named Medical Director (Dr. Ruth Cohen) disclosed on-site
- LegitScript-certified badge displayed; fast 2-3 day shipping claimed
The tradeoffs
- Brand-only and expensive: the real floor is $1,399/mo (Ozempic/Mounjaro), not the $1,299 the homepage FAQ separately claims — the two figures don't reconcile
- The lowest Zepbound figure shown ($1,599) is a one-time new-customer discount off a $1,699 standing price, not an ongoing rate
Hers
58/100Where the value is
- Sells only FDA-approved branded medications (Wegovy, Zepbound, Ozempic, Mounjaro) rather than compounded versions
- Multiple formats per drug (pill vs pen/vial), including a newer pill option and microdosing plan
- Large, publicly traded parent (Hims & Hers Health) with an established clinical/support infrastructure
The tradeoffs
- The advertised 'From $X/mo' price is medication-only — a mandatory membership fee ($39 first month, then $149/mo, billed separately) is layered on top and roughly doubles the real steady-state monthly cost
- No compounded, lower-cost semaglutide/tirzepatide option was found on the current site
Regulatory note: the FDA issued a warning letter to Hims & Hers Health, Inc. dba Hers in September 2025. We still list and link to Hers; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.